Does Medicare Advantage Cover Dayvigo (Lemborexant)?

How Medicare Advantage Plans Handle Dayvigo Coverage

Medicare Advantage (MA) plans that include Part D prescription drug benefits can cover Dayvigo for the treatment of insomnia. Coverage is not automatic. Each MA plan builds its own formulary within the boundaries set by the Centers for Medicare & Medicaid Services (CMS), so the specific tier, copay, and utilization management rules vary from carrier to carrier [3].

CMS requires every Part D formulary to include at least two drugs per therapeutic class. The sedative-hypnotic and insomnia class is broad enough that plans have flexibility in which agents they prefer. Most formularies include zolpidem (generic Ambien) and trazodone as preferred options because they cost a fraction of branded alternatives. Dayvigo, as a newer branded DORA, typically lands on Tier 3 or Tier 4 [4]. A 2023 analysis of Part D formulary data found that only 38% of standalone Part D plans listed Dayvigo without restrictions, while 52% imposed prior authorization and 10% excluded it entirely in favor of suvorexant (Belsomra) or other agents [5].

Your plan's Annual Notice of Change (ANOC) document, mailed each September, will list any formulary shifts for the coming year. If Dayvigo was covered in 2025 but is being moved or removed for 2026, that document is where you will find it.

Prior Authorization: What Your Plan Will Ask For

Prior authorization is the single biggest barrier to filling a Dayvigo prescription under Medicare Advantage. Plans want documentation that the prescriber has a clinical rationale for choosing a branded DORA over cheaper generics.

Standard PA criteria across most MA carriers follow a predictable pattern. The prescriber must confirm a diagnosis of insomnia disorder per DSM-5 criteria, document that non-pharmacologic approaches (such as cognitive behavioral therapy for insomnia, or CBT-I) were considered, and show that the patient tried and failed at least one preferred formulary agent [6]. CBT-I is recommended as first-line treatment for chronic insomnia by the American Academy of Sleep Medicine (AASM), and many plans now reference this guideline explicitly in their coverage determination letters [7].

The turnaround time for a standard PA decision is 72 hours under CMS rules. Expedited requests, appropriate when a delay could seriously harm the patient, must be resolved within 24 hours [3]. If the PA is denied, the plan must issue a written coverage determination explaining the reason and outlining your appeal rights.

Common denial reasons include: no documented trial of a preferred agent, missing sleep study or clinical notes, or a diagnosis code that does not match the approved indication. A clean submission with chart notes attached at the outset reduces denial rates significantly.

Formulary Tier and What You Will Pay

Dayvigo sits on Tier 3 (non-preferred brand) or Tier 4 (specialty/non-preferred) on the majority of Medicare Advantage Part D formularies. The tier assignment directly determines your out-of-pocket cost.

On a Tier 3 placement, expect copays in the $42 to $75 range for a 30-day supply. Tier 4 copays can run $75 to $100 or higher, depending on the plan's cost-sharing structure [4]. These figures apply during the Initial Coverage Phase. Once your total drug spending crosses the Initial Coverage Limit ($5 to 030 in 2025), you enter the Coverage Gap phase, where cost-sharing rules shift. The Inflation Reduction Act caps total out-of-pocket Part D spending at $2,000 annually beginning in 2025, which provides a hard ceiling for beneficiaries taking multiple branded medications [8].

For comparison, generic zolpidem typically costs $3 to $10 per month on a Tier 1 or Tier 2 copay. Generic trazodone runs $4 to $12. The price gap explains why plans push step therapy toward these agents first. Suvorexant (Belsomra), the other branded DORA, carries similar Tier 3 or Tier 4 placement and comparable copays, so switching between DORAs rarely saves money within the same plan.

Step Therapy Requirements Before Dayvigo

Step therapy (also called "fail first") is a utilization management tool that requires you to try one or more lower-cost medications before the plan will approve a higher-tier drug. Most Medicare Advantage plans impose step therapy on Dayvigo.

The typical step sequence requires a documented trial of at least one of the following: zolpidem (immediate or extended release), trazodone, or eszopiclone [6]. Some plans accept suvorexant as a step-therapy equivalent since it shares the same DORA mechanism, though this is less common. A "documented trial" generally means 14 to 30 days of use at an adequate dose, with chart notes describing why the medication was ineffective, poorly tolerated, or contraindicated.

Contraindications can bypass step therapy entirely. If a patient has a history of complex sleep behaviors on Z-drugs (sleepwalking, sleep-driving), the FDA's 2019 boxed warning on zolpidem, eszopiclone, and zaleplon provides clinical grounds for skipping directly to a DORA [9]. The prescriber should cite this warning in the PA request. Patients with a substance use disorder history may also qualify for a step-therapy exception, since Z-drugs carry DEA Schedule IV classification and a recognized misuse liability that DORAs do not share to the same degree [10].

SUNRISE-1 (N=1,006), the registration trial for lemborexant, demonstrated that both the 5 mg and 10 mg doses produced statistically significant reductions in latency to persistent sleep (LPS) and wake after sleep onset (WASO) compared to placebo at one month. The 10 mg dose reduced LPS by 10.5 minutes more than placebo (P<0.001) [2]. SUNRISE-2, the six-month extension study, confirmed sustained efficacy without evidence of rebound insomnia or withdrawal upon discontinuation, a finding that distinguishes DORAs from benzodiazepine receptor agonists [11].

These trial results are the strongest clinical use points when building a step-therapy exception or appeal.

How to Appeal a Medicare Advantage Denial of Dayvigo

A denial is not the end. Medicare Advantage plans operate under a federally mandated, multi-level appeal process that gives beneficiaries several chances to overturn an unfavorable decision.

Level 1: Plan Reconsideration. You or your prescriber file a written appeal with the plan within 60 days of the denial. Include supporting clinical documentation: chart notes, prior medication trials with dates and outcomes, relevant lab work, and a letter of medical necessity from the prescriber. The plan must decide within 7 days (standard) or 72 hours (expedited) [3].

Level 2: Independent Review Organization (IRO). If the plan upholds the denial, it automatically forwards the case to an IRO for independent review. The IRO has 7 days for standard requests. Approximately 40% of Part D IRO appeals result in full or partial reversals, according to CMS data from 2023 [12].

Level 3: Office of Medicare Hearings and Appeals (OMHA). If the amount in controversy meets the threshold ($185 in 2025), you can request an Administrative Law Judge (ALJ) hearing. This stage is rarely needed for single-drug coverage disputes but remains available.

Level 4 and 5: Medicare Appeals Council and Federal District Court. These final levels apply to complex or high-dollar disputes and are uncommon for individual prescription appeals.

The most effective appeal letters reference the specific plan formulary criteria, explain point-by-point how the patient meets or should be excepted from each requirement, and attach the AASM clinical practice guideline recommending orexin receptor antagonists as an option for chronic insomnia [7]. A peer-to-peer call between the prescriber and the plan's medical director can also resolve disputes before they escalate.

Can You Use the Eisai Savings Card with Medicare?

No. Federal anti-kickback statutes prohibit Medicare beneficiaries from using manufacturer copay cards or savings programs for Part D-covered drugs [13]. Eisai's Dayvigo savings card, which can reduce out-of-pocket costs to as little as $30 per month for commercially insured patients, is explicitly restricted to individuals with commercial (private, non-government) insurance.

Medicare Advantage enrollees seeking cost relief have other options. Eisai operates a patient assistance program (PAP) for qualifying low-income patients. Eligibility typically requires income at or below 400% of the federal poverty level and enrollment in a Medicare plan [14]. The application process takes 4 to 6 weeks. Extra Help (Low-Income Subsidy), administered by the Social Security Administration, can reduce Part D copays to $0 to $11 per prescription for qualifying beneficiaries, regardless of tier [8].

If your plan places Dayvigo on Tier 4 and the copay exceeds your budget, ask your prescriber about a formulary tier exception request. CMS rules require plans to grant a tier reduction if the prescriber demonstrates that all preferred-tier alternatives are ineffective or would cause adverse effects for the specific patient [3].

Dayvigo vs. Other Covered Insomnia Options on Medicare

Choosing between insomnia medications on a Medicare Advantage formulary involves balancing efficacy data, safety profile, and cost-sharing.

Generic zolpidem remains the most commonly prescribed insomnia drug on Part D plans. It works. But the FDA's 2019 contraindication update for patients with a history of complex sleep behaviors narrowed its safe use [9]. Trazodone, prescribed off-label for insomnia at 25 to 100 mg, is inexpensive and sedating, yet lacks strong RCT data specifically in insomnia populations and carries next-day grogginess and orthostatic hypotension risks in older adults [15].

Suvorexant (Belsomra), the first FDA-approved DORA, showed efficacy in the phase III trials but at a narrower dose range (10 to 20 mg) than lemborexant. A head-to-head comparison has not been conducted in a powered RCT, though indirect treatment comparisons suggest similar efficacy profiles between the two DORAs [16]. On most formularies, suvorexant and lemborexant occupy the same tier and carry comparable copays, so switching between them is rarely a financial strategy.

Lemborexant's label includes data in patients aged 55 and older from SUNRISE-1, which enrolled a substantial proportion of elderly subjects. The DORA class avoids the anticholinergic burden, fall risk elevation, and cognitive impairment associated with benzodiazepines and antihistamines (diphenhydramine, doxepin at sedating doses) that appear on the American Geriatrics Society Beers Criteria list of potentially inappropriate medications for older adults [17]. For Medicare beneficiaries, who skew older by definition, this safety profile is a meaningful differentiator in clinical decision-making.

Timing Your Coverage: Open Enrollment and Special Enrollment

If your current Medicare Advantage plan does not cover Dayvigo or places it on an unfavorable tier, you can switch plans during the Annual Enrollment Period (AEP) from October 15 through December 7 each year. Changes take effect January 1 [8].

The Medicare Plan Finder tool at medicare.gov lets you enter your specific medications and compare formulary placement, copays, and restrictions across every MA plan available in your ZIP code. Enter "lemborexant" or "Dayvigo" along with your other prescriptions to see which plans offer the most favorable terms.

Outside AEP, a Special Enrollment Period (SEP) may apply if you qualify due to a move, loss of other coverage, or certain chronic conditions. The Chronic Condition SEP allows one plan switch per quarter (January through September) for beneficiaries with specific diagnoses, though insomnia alone does not currently qualify [8].